Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma

NCT00387335 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00387335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00387335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2006
Completion date
March 31, 2010
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the nasopharynx, stage iv squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity